Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythromycin versus metoclopramide for gastrointestinal dysmotility in premature infants
IRCT20220524054983N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Gastrointestinal Dysmotility comparing Erythromycin arm with Metoclopramide arm (2 arms). Primary endpoints: Feces volume, Daily vomiting frequency and 2 more. Started Jan 2024; status: completed.
02
Drugs
erythromycinmetoclopramide
03
Conditions
Gastrointestinal Dysmotility
Beyond the preview
Go deeper on IRCT20220524054983N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220524054983N1.